Dyne Therapeutics (DYN) AI Stock Analysis

• Market Cap: $2.96B
• Dividend Yield: N/A
• Average Volume (3M): 2.13M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.76
• Revenue Growth: N/A
• EPS Growth: -2.75%
• Country: US
• Employees: 192
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.76
• Shares Outstanding: 165,027,110
• 10 Day Avg. Volume: 2,935,571
• 30 Day Avg. Volume: 2,127,201
• PEG Ratio: -1.90
• Price to Book (P/B): 2.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.20
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -4.00K
• Enterprise Value/Ebitda: -4.76
• 1Y Price Target: $39.13
• Price Target Upside: 118.33% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -3.17
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: $18.50 ▲(3.24% Upside)
• Action: Reiterated Date: 03/11/26
• Date: Action: Reiterated 03/11/26

The score is primarily constrained by continued pre-revenue operations with widening losses and accelerating cash burn, despite a strong, low-leverage balance sheet. Technicals show an uptrend but with mixed momentum signals, while valuation support is limited due to a negative P/E and no dividend. Corporate updates are positive, citing encouraging clinical progress and significant cash runway.

Positive Factors

Low leverage and strong asset base

A very low debt-to-equity ratio and a sizable asset base provide durable financial flexibility for a development-stage biotech. This reduces near-term refinancing pressure, supports multi-year R&D programs, and preserves optionality to fund registrational trials or partnerships without immediate high interest burden.

FORCE delivery platform with clinical validation

Clinical topline success for a registrational cohort and validation of a targeted antibody-based delivery platform strengthen a sustainable competitive edge. A durable, muscle-targeted delivery capability can enable multiple oligonucleotide programs, driving pipeline scalability and long-term differentiation in neuromuscular therapeutics.

Loaded cash runway into 2028

A large cash balance with an explicit runway into Q1 2028 materially reduces immediate financing risk and allows management to execute registrational work and regulatory filings. This steadies the path to potential commercialization and de-risks near-term program funding and milestone delivery timelines.

Negative Factors

Pre-revenue company

Absence of product revenue means long-term value depends entirely on successful clinical outcomes, regulatory approval, and future commercialization or licensing. This structural revenue gap increases execution risk and creates dependence on non-operating income sources until products reach market and generate sustainable sales.

Accelerating negative cash flow

Rapidly rising operating and free cash outflows signal escalating funding needs. Even with current runway, sustained high burn increases likelihood of dilutive equity financings or partnership dependency, reducing financial resilience if clinical timelines slip or additional trials are required before revenue generation.

Widening losses and negative returns on equity

Deepening annual losses and a highly negative ROE reflect capital consumption and limited near-term shareholder returns. Over time this can constrain strategic choices, increase pressure for external funding, and dilute long-term equity value if clinical or commercial milestones are delayed or fail to materialize.

Dyne Therapeutics Business Overview & Revenue Model

Company Description

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

How the Company Makes Money

As a clinical-stage biopharmaceutical company, Dyne’s revenue, when present, is primarily generated from collaborations and licensing arrangements (e.g., upfront payments, research funding, and potential development, regulatory, and sales-based milestone payments, plus potential royalties) rather than from product sales, because its product candidates are still in development. The company’s cash generation has also historically depended on financing activities—such as issuing equity in public or private offerings and, where applicable, other capital-raising transactions—to fund R&D and operations. Product revenue from commercial drug sales is null because there are no publicly disclosed approved Dyne products for sale as of this response.

Dyne Therapeutics Financial Statement Overview

Summary

Balance sheet strength and low leverage (debt-to-equity ~0.02; assets ~$1.19B) support near-term operations, but the company remains pre-revenue with sharply widening losses (net loss ~-$446M in 2025) and accelerating cash burn (operating cash flow ~-$403M; free cash flow ~-$405M in 2025), increasing longer-term funding risk.

Income Statement

Dyne Therapeutics remains pre-revenue (revenue is $0 across 2020–2025), with losses widening materially over time. Net loss increased from about $59M (2020) to about $446M (2025), and EBIT/EBITDA losses similarly expanded (EBIT about -$468M in 2025). The key strength is that the company is investing heavily toward future commercialization, but the main weakness is the lack of revenue base and consistently deepening profitability profile.

Balance Sheet

The balance sheet is a relative bright spot: leverage is low, with debt-to-equity improving to ~0.02 in 2025 (total debt ~$20M against equity ~$972M). Total assets rose substantially to ~$1.19B in 2025, reflecting a strong funding position for a development-stage biotech. The weakness is persistent negative returns on equity (about -46% in 2025) driven by large losses, which can pressure capital over time if burn remains elevated.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow consistently negative and the cash burn accelerating (operating cash flow from about -$47M in 2020 to about -$403M in 2025; free cash flow about -$405M in 2025). A positive is that free cash flow generally tracks net income closely (free cash flow to net income ~1.0 in recent years), suggesting losses are largely reflected in cash usage rather than hidden working-capital effects. The key risk is the scale and upward trend of cash burn, which increases dependence on external financing.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-2.05M	-2.24M	-2.46M	0.00	0.00
EBITDA	-437.97M	-315.18M	-233.48M	-169.28M	-148.94M
Net Income	-446.21M	-317.42M	-235.94M	-168.10M	-149.29M
Balance Sheet
Total Assets	1.19B	691.23M	165.08M	306.32M	425.66M
Cash, Cash Equivalents and Short-Term Investments	1.11B	642.27M	123.10M	256.01M	376.57M
Total Debt	20.28M	23.99M	27.41M	30.48M	32.64M
Total Liabilities	214.83M	61.40M	73.79M	53.96M	57.47M
Stockholders Equity	972.13M	629.84M	91.29M	252.36M	368.20M
Cash Flow
Free Cash Flow	-405.13M	-294.75M	-188.89M	-156.71M	-123.18M
Operating Cash Flow	-403.21M	-292.37M	-188.16M	-153.65M	-119.56M
Investing Cash Flow	-28.75M	-204.08M	83.31M	87.20M	-137.89M
Financing Cash Flow	890.31M	809.89M	54.32M	37.39M	157.82M

Dyne Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 17.92
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Positive. The current price of 17.92 is above the 20-day moving average (MA) of 16.24, above the 50-day MA of 17.11, and above the 200-day MA of 15.30, indicating a bullish trend. The MACD of 0.34 indicates Negative momentum. The RSI at 55.15 is Neutral, neither overbought nor oversold. The STOCH value of 76.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DYN.

Dyne Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	63 Neutral	$2.82B	-228.91	-10.26%	―	129.21%	80.35%
DYN	56 Neutral	$2.96B	-5.63	-61.45%	―	―	-2.75%
BEAM	54 Neutral	$2.56B	-34.27	-7.31%	―	-84.07%	-157.71%
IMCR	53 Neutral	$1.56B	-19.61	-6.93%	―	27.51%	38.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COGT	49 Neutral	$5.52B	-5.86	-100.22%	―	―	4.32%
SRPT	48 Neutral	$1.72B	-3.16	-57.52%	―	47.15%	-311.26%

Dyne Therapeutics Corporate Events

Dyne Therapeutics Highlights Pipeline and Cash at JPM Conference

On January 12, 2026, Dyne Therapeutics released an investor presentation at the J.P. Morgan Healthcare Conference outlining its current operations, late-stage clinical pipeline and plans to advance its FORCE platform-based neuromuscular therapies toward commercialization. The company highlighted positive topline data from a registrational cohort of its Duchenne muscular dystrophy candidate zeleciment rostudirsen, ongoing registrational work in myotonic dystrophy type 1, and a strong cash position of roughly $1.1 billion as of December 31, 2025, supporting operations into the first quarter of 2028 and enabling a steady schedule of data readouts and regulatory submissions ahead of a targeted first commercial launch in early 2027; together with emerging clinical validation of its targeted delivery technology, these developments position Dyne as a potential best-in-class player in rare neuromuscular disease and signal material implications for future revenue generation and competitive standing in the sector.

The most recent analyst rating on (DYN) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.

Dyne Therapeutics Appoints Vikram Karnani to Board

On December 22, 2025, Dyne Therapeutics, Inc.’s board of directors elected Vikram Karnani as an independent Class II director, with a term running until the company’s 2028 annual meeting of stockholders, signaling continued attention to board independence and governance. Karnani will receive standard non-employee director compensation, including an option to purchase 59,665 shares at $20.78 per share vesting over three years, annual cash and equity compensation, and reimbursement of board-related expenses, with no related-party relationships or transactions disclosed and with his role governed by the company’s standard indemnification agreement.

The most recent analyst rating on (DYN) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.